Follow us on Twitter
twitter icon@FreshPatents


Atherosclerosis patents

      

This page is updated frequently with new Atherosclerosis-related patent applications.




 Trka kinase inhibitors, compositions and methods thereof patent thumbnailTrka kinase inhibitors, compositions and methods thereof
The present invention is directed to a bicyclic heteroaryl benzamide compounds of formula (i) which are tropomyosin-related kinase (trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (ngf) receptor trka.. .
Merck Sharp & Dohme Corp.


 Urea compounds and their use as enzyme inhibitors patent thumbnailUrea compounds and their use as enzyme inhibitors
Or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, parkinson's disease, levodopa-induced dyskinesia, huntington's disease, gilles de la tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, alzheimer's disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, emesis, alcohol disorders, drug addictions such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, myocardial reperfusion injury, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease, acute and chronic liver disease such as hepatitis and liver cirrhosis, arthritis and osteoporosis..

 Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators patent thumbnailCompositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
Provided herein are methods of treating, preventing or managing atherosclerosis by administering a pde4 modulator. Pharmaceutical compositions, dosage forms, and kits suitable for use in methods are also provided..
Celgene Corporation


 Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use patent thumbnailSubstrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use
The presently disclosed inventive concept(s) include inhibitors of antiplasmin cleaving enzyme (apce) and fibroblast activation protein alpha (fap) which can be used in various therapies related to disorders of fibrin and α2-antiplasmin and abnormal cell proliferation. The presently disclosed inventive concept(s) also include substrates of apce and fap, which may be used, for example, in screening methods for identifying such inhibitors.
The Board Of Regents Of The University Of Oklahoma


 Composition for imaging atherosclerosis and  diagnosing atherosclerosis by using same patent thumbnailComposition for imaging atherosclerosis and diagnosing atherosclerosis by using same
The present disclosure relates to a composition for imaging atherosclerosis and a method for diagnosing atherosclerosis using the same. The composition for imaging atherosclerosis according to the present disclosure shows excellent atherosclerosis diagnosis accuracy, enables diagnosis of atherosclerosis even for a person with diseases of glucose metabolism such as diabetes and enables effective diagnosis even for atherosclerosis occurring in the brain and heart.
Seoul National University R&db Foundation


 High throughput biochemical fluorometric  measuring hdl redox activity patent thumbnailHigh throughput biochemical fluorometric measuring hdl redox activity
In various embodiments, a new, robust fluorometric cell-free biochemical assay that measures hdl redox activity (hra) is provided. In certain embodiments the assay is based on the oxidation of the fluorochrome amplex® red in the presence of hrp.
The Regents Of The University Of California


 Heteroaromatic compounds and their use as dopamine d1 ligands patent thumbnailHeteroaromatic compounds and their use as dopamine d1 ligands
And pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating d1-mediated (or d1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, ad, pd, or pharmacotherapy therapy), adhd, impulsivity, compulsive gambling, overeating, autism spectrum disorder, mcl, age-related cognitive decline, dementia, rls, parkinson's disease, huntington's chorea, anxiety, depression, mdd, trd, bipolar disorder, chronic apathy, anhedonia, chronic fatigue, post-traumatic stress disorder, seasonal affective disorder, social anxiety disorder, post-partum depression, serotonin syndrome, substance abuse and drug dependence, drug abuse relapse, tourette's syndrome, tardive dyskinesia, drowsiness, excessive daytime sleepiness, cachexia, inattention, sexual dysfunction, migraine, sle, hyperglycemia, atherosclerosis, dislipidemia, obesity, diabetes, sepsis, post-ischemic tubular necrosis, renal failure, hyponatremia, resistant edema, narcolepsy, hypertension, congestive heart failure, postoperative ocular hypotonia, sleep disorders, and pain.. .

 Substituted pyridazines as prostacyclin receptor modulators patent thumbnailSubstituted pyridazines as prostacyclin receptor modulators
Cyclohexane derivatives of formula ia and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (sle); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (copd)..
Arena Pharmaceuticals, Inc.


 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors patent thumbnail3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
(wherein r1, r2, r3, r4, r5, r6, r7, x, y and z are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of chemokine receptors and more specifically as modulators of the ccr2 and/or ccr5 receptor.

 Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome patent thumbnailCompositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome
The present invention relates to compositions and methods for treating diseases associated with dyslipidemia, including hypercholesterolemia, hypertriglyceridemia, steatohepatitis, atherosclerosis, obesity, hyperglycemia, metabolic syndrome, and related aspects of and conditions associated with metabolic syndrome. The compositions and methods disclosed herein are useful for regulating the lipid balance (lipid homeostasis) in a subject.
Vanderbilt University


Antibody therapeutics that bind cd147

There is disclosed compositions and methods relating to or derived from anti-cd147 antibodies. More specifically, there is disclosed fully human antibodies that bind cd147, cd147-binding fragments and derivatives of such antibodies, and cd147-binding polypeptides comprising such fragments.
Sorrento Therapeutics, Inc.

Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof

The invention provides various novel compositions of berberine in combination with pharmacologically active organic acids, and related methods of their use in treating various diseases or disorders. The invention further provides various novel compounds prepared from berberine and pharmacologically active organic acids and prepared from ursodeoxycholic acid and pharmacologically active organic bases, and pharmaceutical compositions thereof, and methods of their preparation and therapeutic use in treating and/or preventing various diseases or disorders.
Shenzhen Hightide Biopharmaceutical, Ltd.

Prodrug of an ice inhibitor

Compound i is useful for treating il-1 mediated diseases such as rheumatoid arthritis, inflammatory bowel disease, crohn's disease, ulcerative colitis, inflammatory peritonitis, septic shock, pancreatitis, traumatic brain injury, organ transplant rejection, osteoarthritis, asthma, psoriasis, alzheimer's disease, myocardial infarction, congestive heart failure, huntington's disease, atherosclerosis, atopic dermatitis, leukemias and related disorders, myelodysplastic syndrome, uveitis or multiple myeloma.. .

Use of a statin compound as topical drug for treating obesity, diabetes, hypertension and hyperlipemia

The invention discloses a use of a statin compound in the preparation of local drugs for improving lipid metabolism and treating obesity, hypertension, hyperlipidemia, fatty liver and hyperglycemia; and statin compound local compositions for improving lipid metabolism and treating obesity, hypertension, fatty liver, hyperlipidemia, atherosclerosis, coronary heart disease, apoplexy and other cardiovascular and cerebrovascular diseases, and drug formulation and preparation method thereof.. .
Peking University Third Hospital

Method of evaluation of the relative risk of developing atherosclerosis in patients

The present invention relates to a method for determining the amount of circulating cd36 protein or a fraction thereof which is present in cell-free plasma, preferably in a high molecular weight plasma fraction, such as a lipoprotein fraction selected from low density lipoprotein, intermediate density lipoprotein, and very low density lipoprotein using an immunological method which comprises the steps of (i) providing a plasma sample to be investigated, (ii) providing an anti-cd36 antibody, (iii) exposing the sample to be investigated to the antibody, and (iv) detecting and quantifying the amount of cd36 which binds to the antibody.. .
Region Nordjylland

Lipidomic biomarkers for atherosclerosis and cardiovascular disease

The present invention inter alia provides a method, and use thereof, of diagnosing and/or predicting atherosclerosis or cvd by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in detecting and predicting atherosclerosis and cvd than currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating atherosclerosis or cvd.
Zora Biosciences Oy

Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as cdk inhibitors and their therapeutic use

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds (referred to herein as “ppda compounds”) that, inter alia, inhibit (e.g., selectively inhibit) cdk (e.g., cdk1, cdk2, cdk4, cdk5, cdk6, cdk7, cdk8, cdk9, cdk10, cdk11, cdk12, cdk13, etc.).
Emory University

Compositions based on methyl cyclodextrins for the treatment and/or prevention of diseases by increasing the hdl cholesterol level

The invention relates to a novel use of a pharmaceutical composition comprising at least one methyl cyclodextrin having a molar substitution (ms) degree of between 0.05 and 1.5 in the treatment and/or prevention of diseases that can be treated and/or prevented by an increase in the hdl cholesterol level. The invention also relates to the use thereof in the treatment and/or prevention of atherosclerosis or complications relating to an atheroma, and/or diseases of the central nervous system.
Roquette Freres

Furo[3, 2-b] pyrr0l-3-ones as cathespin s inhibitors

Compounds of formula (i) exhibit surprisingly high efficacies for human cathepsin s, excellent selectivity verses other mammalian cathepsins and are useful for treatment of diseases such as rheumatoid arthritis, multiple sclerosis, myasthenia gravis, transplant rejection, diabetes, sjogrens syndrome, grave's disease, systemic lupus erythematosis, osteoarthritis, psoriasis, idiopathic thrombocytopenic purpura, allergic rhinitis, asthma, atherosclerosis, obesity, chronic obstructive pulmonary disease and chronic pain.. .

Method for selectively inhibiting acat1 in the treatment of obesity, metabolic syndrome, and atherosclerosis

The present invention features methods for preventing and treating three related diseases, diet-induced obesity, metabolic syndrome, and atherosclerosis, alone or in combination by inhibiting acyl-coa: cholesterol acyltransferase 1 (acati) activity or expression in myeloid cells.. .
Trustees Of Dartmouth College

Novel cholesterol metabolite, 5-cholesten, 3beta-25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty livers diseases and atherosclerosis

5-cholesten, 3β, 25-diol, disulfate (25hcds) has been found to be an authentic pparγ agonist and lxr antagonist, and is used for the therapy of lipid disorders and inflammatory diseases, including without limitation fatty liver, inflammatory bowel, and atherosclerotic diseases.. .
Virginia Commonwealth University

3,3'-disubstituted indolines as inhibitors of cholesterol ester transfer protein

3,3′-disubstituted indoline compounds, including pharmaceutically acceptable salts of the compounds, are cetp inhibitors and are useful for raising hdl-cholesterol, reducing ldl-cholesterol, and for treating or preventing atherosclerosis.. .
Merck Sharp & Dohme Corp.

Beta-lactam cholesterol absorption inhibitors

The present invention relates to the novel compounds represented by formula (ia) or (ib) and to their pharmaceutical preparations for the treatment of atherosclerosis and cholesterol level reduction.. .
Rudjer Boskovic Institute

Novel processes

The compounds of formula (i) being useful for treating cardiovascular and inflammatory diseases such as atherosclerosis.. .

Compositions and therapeutic methods for accelerated plaque regression

The invention comprises methods for treating and/or preventing cardiovascular, cholesterol, and lipid related disorders, including atherosclerosis, through-co-administration of therapeutically effective amounts of a compound of formula i or a pharmaceutically acceptable salt thereof and rosuvastatin or pravastatin or a pharmaceutically acceptable salt of rosuvastatin or pitavastatin. The invention further provides compositions comprising a therapeutically effective amount of a compound of formula i or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of or pitavastatin or a pharmaceutically acceptable salt of rosuvastatin or pitavastatin..
Resverlogix Corp

Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders

Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders..
The Johns Hopkins University

Thienomethylpiperazine derivatives as inhibitors of soluble epoxide hydrolase

The present invention relates to compounds of the formula (i), wherein r1, r2, r3, r4 and x have the meanings indicated in the claims. The compounds of formula i are valuable pharmacologically active compounds.
Sanofi

Methods and compositions relating to p62/sqstm1 for the treatment and prevention of inflammation-associated diseases

Provided herein are novel p62 compositions for the modulation of expression of a proinflammatory cytokines, osteogenic transcription factors, a bone resorptive factors and endogenous p62. Consequently, such p62 compositions are useful for prophylaxis and treatment of inflammatory diseases and related methods.
Curelab Oncology, Inc.

Method of inhibiting the glycation of nutrient and endogenous proteins and peroxidation of nutrient and endogenous lipids

Methods for reducing the glycation of nutrient and endogenous proteins and methods for reducing the peroxidation of nutrient and endogenous lipids are provided herein. Several inhibitors and conditions of inhibiting glycation of nutrient and endogenous proteins and peroxidation of nutrient and endogenous lipids are also provided herein.

Method for pre-screening and correlation of underlying scarb1 gene variation to atherosclerosis in women and therapeutic use of progestational and other medications in treatment

A method of genotyping women experiencing infertility for non-physical reasons in order to identify the presence of the rs4238001 and/or rs10846744 mutation of the scarb1 gene and, upon identifying the presence of one or both genetic mutations, administering a tailored therapeutic regimen to restore fertility by either one or a combination of 1) mediating the flux of cholesterol resulting from the mutation by therapeutic use of the cholesterol medication probucol and/or other cholesterol altering medications, and/or 2) amplifying the presence of hormone progesterone by therapeutic use of progestational and progestin medications.. .

Fused bicyclic isoxazolines as inhibitors of cholesterol ester transfer protein

Compounds having the structure of formula i, including pharmaceutically acceptable salts of the compounds, wherein x is (ch2) or o, are cetp inhibitors and are useful for raising hdl-cholesterol, reducing ldl-cholesterol, and for treating or preventing atherosclerosis:. .
Merck Sharp & Dohme Corp.

Uses of kappa opioid synthetic peptide amides

The invention relates to methods of use of synthetic peptide amides that are ligands of the kappa opioid receptor in the treatment and prevention of kappa opioid receptor-associated diseases and conditions; and particularly to uses of these agonists in the prophylaxis, inhibition and treatment of pain, inflammation and pruritis associated with a variety of diseases, disorders and conditions. Inflammatory conditions preventable or treatable by the methods of the invention include diseases and conditions associated with elevated levels of a proinflammatory cytokines, such as tnf-α, il-1β, il-6, mmp-1 and mmp-3.
Cara Therapeutics, Inc.

Combination therapies for treatment of laminopathies, cellular aging, and atherosclerosis

Provided herein are combination therapies for the treatment of progeroid diseases and conditions, cellular aging, bone diseases, and cardiovascular diseases. The provided combination therapies target the aberrant farnesylation of the mutant lamin a protein progerin and increase progerin clearance..

Method for inhibiting cellular activation by insulin-like growth factor-1

A method of inhibiting cellular activation by insulin-like growth factor-1 (igf-1) in a subject in need thereof (e.g., a subject afflicted with cancer, atherosclerosis, diabetic retinopathy or other disease) comprises administering an antagonist that inhibits the binding of iap to shps-1 to the subject in an amount effective to inhibit cellular activation by igf-1. Compounds and compositions for carrying out such methods are also described..
The University Of North Carolina At Chapel Hill

Methods for prevention and treatment of cardiometabolic syndrome and compositions used therein

Beta-cryptoxanthin compositions and methods are described for the management of cardiometabolic syndrome and associated risk factors, in a subject, in need thereof. Methods herein are directed to identifying such subject at risk of developing cardiometabolic syndrome and administering beta-cryptoxanthin composition to assess the condition of an organ.
Omniactive Health Technologies Limited

Pharmaceutical composition for treating a metabolic syndrome

The invention is directed to a pharmaceutical composition containing at least one fgf-21 (fibroblast growth factor 21) compound, at least one glp-1r (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one dpp-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas.. .
Sanofi

Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection

The present invention is directed to pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of an array of the manifestations of metabolic syndromes, including type 2 diabetes, hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the present invention relates to compositions and methods which may be used to treat, inhibit or reduce the likelihood of hepatitis viral infections, including hepatitis b and hepatitis c viral infections, as well as the secondary disease states and/or conditions which are often associated with such viral infections, including hepatic steatosis (steatohepatitis), cirrhosis, fatty liver and hepatocellular cancer, among other disease states or conditions..
Volant Holdings Gmbh

Anti-kir antibodies

Provided herein are compositions (e.g., killer cell immunoglobulin-like receptor (kir)-targeting agents) that target a subset of t lymphocytes present in disease states (e.g., lupus and other autoimmune diseases) and methods of treating conditions and/or diseases therewith. In particular, anti-kir antibodies, fragments thereof, or related compositions are provided for the treatment of conditions and/or diseases (e.g., lupus and other autoimmune diseases, atherosclerosis, etc.)..
The Regents Of The University Of Michigan

Compositions for selective reduction of circulating bioactive soluble tnf and methods for treating tnf-mediated disease

An isolated or synthetic antibody or ligand is provided that specifically binds to an epitope of a dissociated monomer of human tnf. Such binding disrupts assembly of the monomer into bioactive trimeric human stnf.
Thymon, Llc

Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals

Wherein a, y, z, r3 to r6, r20 to r22 and r50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (edg-2, edg2), which is activated by lysophosphatidic acid (lpa) and is also termed as lpa1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example.

Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis

The sulfated oxysterol 5-cholesten-3β, 25-diol 3-sulphate, a nuclear cholesterol metabolite that decreases lipid biosynthesis and increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and/or triglycerides, and to prevent or treat lipid accumulation-associated inflammation and conditions associated with such inflammation. Methods which involve the use of this sulfated oxysterol to treat conditions associated with high cholesterol and/or high triglycerides and/or inflammation (e.g.
Virginia Commonwealth University

Antibody therapeutics that bind jag1

There is disclosed compositions and methods relating to or derived from anti-jag1 antibodies. More specifically, there is disclosed fully human antibodies that bind jag1, jag1-binding fragments and derivatives of such antibodies, and jag1-binding polypeptides comprising such fragments.
Sorrento Therapeutics, Inc.

The present invention provides cyclic compounds that are useful in preventing or treating atherosclerosis or related disorders. The invention also provides therapeutic methods for treating or preventing various diseases or disorders associated with or mediated by atherosclerosis.
The Scripps Research Institute

Antioxidant compound having anti atherosclerotic effect and preparation thereof

The present invention relates to an antioxidant compound having anti atherosclerotic effect and preparation thereof. The present invention more particularly relates to the synthesis of tpp+ coupled esculetin (mitochondria-targeted esculetin [mito-esc]) followed by the biological evaluation of mito-esc for its ability to attenuate angiotensin-ii-induced atherosclerosis in apolipoproteine knockout (apoe−/−) mice along with the endothelial cell age-delaying effects of mito-esc..
Council Of Scientific And Industrial Research

Rny-derived small rnas as biomarkers for atherosclerosis-related disorders

The present invention concerns an in vitro method of diagnosis or prognosis of an atherosclerosis-related disorder by detecting a small y rna (s-rny), as well as the use of an inhibitor of s-rny as a medicament against atherosclerosis-related disorders. The invention also concerns a method for screening for a compound suitable for the treatment of an atherosclerosis-related disorder..
Universite De Nice Sophia Antipolis

3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals

Wherein ht, g, r10, r30, r40, r50 and r60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin a, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example.

Trka kinase inhibitors, compositions and methods thereof

The present invention is directed to benzyl urea compounds of formula (i) which are tropomyosin-related kinase (trk) family protein kinase inhibitors, and hence may be useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (ngf) receptor trk-a, trk-b and/or trk-c.. .
Merck Sharp & Dohme Corp.

Benzazepine ketone compounds as glycogen phosphorylase inhibitor, preparation method therefor, and medical uses

The present invention relates to the field of pharmaceutical chemistry, and particularly to a novel class of benzazepine ketone derivatives (i), their preparation method and their pharmaceutical uses. The compounds have glycogen phosphorylase inhibiting effect and can be used in the preparation of anti-diabetes and its complications medicaments, anti-cerebral ischemia medicaments, anti-cardiovascular diseases medicaments, blood lipid-lowering medicaments, weight-reducing medicaments, anti-atherosclerosis medicaments, medicaments for treating metabolic syndrome or anti-tumor medicaments.
Chengde Medical University

Cyanotriazole compounds

Wherein each symbols are defined in the specification, or a salt thereof. The compound or a salt thereof stimulates the citric acid cycle activity and/or improves hyperglycemia with less side effects, and excellent safety, and therefore, it is useful for treating and/or preventing diseases or disorders on which citric acid cycle activation and/or improvement of hyperglycemia has a prophylactic and/or therapeutic effect, for example, diabetes, impaired glucose tolerance, insulin resistance, diabetic complications, obesity, dyslipidemia, hepatic steatosis, atherosclerosis and/or cardiovascular disease, as well as diseases or disorders that would benefit from stimulating energy expenditure..

Trka kinase inhibitors, compositions and methods thereof

The present invention is directed to benzyl urea compounds of formula (i) which are tropomyosin-related kinase (trk) family protein kinase inhibitors, and hence may be useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (ngf) receptor trk-a, trk-b and/or trk-c.. .
Merck Sharp & Dohme Corp.

Methods for treating cancer with trka receptor tyrosine kinase antagonists

The disclosure further concerns the use of such compounds in the treatment and/or prevention of certain types of cancers, pain, inflammation, restenosis, atherosclerosis, psoriasis, thrombosis, alzheimer's, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination.. .



Atherosclerosis topics:
  • Atherosclerosis
  • Insulin Resistance
  • Cardiovascular Disease
  • Cardiovascular
  • Vascular Diseases
  • Vascular Disease
  • Liver Disease
  • Hyperlipidemia
  • Fatty Liver
  • Inflammation
  • Metabolic Disorder
  • Renal Failure
  • Dyslipidemia
  • Nephropathy
  • Polypeptide


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Atherosclerosis for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Atherosclerosis with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.3404

    file did exist - file did put2598

    4 - 1 - 51